

**TOXICOLOGICAL PROFILE FOR  
METHYLENEDIANILINE**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES**  
**Public Health Service**  
Agency for Toxic Substances and Disease Registry

August 1998

## **DISCLAIMER**

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

## UPDATE STATEMENT

A Toxicological Profile for methylenedianiline was released in October 1995. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry  
Division of Toxicology/Toxicology Information Branch  
1600 Clifton Road NC, E-29  
Atlanta, Georgia 30333



## FOREWORD

This toxicological profile is prepared in accordance with guidelines\* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.


The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Claire V. Broome, M.D.  
Acting Administrator  
Agency for Toxic Substances and  
Disease Registry

The toxicological profiles are developed in response to the Super-fund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Super-fund). Section 211 of SARA also amended Title 10 of the U. S. Code, creating the Defense Environmental Restoration Program. Section 2704(a) of Title 10 of the U. S. Code directs the Secretary of Defense to notify the Secretary of Health and Human Services of not less than 25 of the most commonly found unregulated hazardous substances at defense facilities. Section 2704(b) of Title 10 of the U. S. Code directs the Administrator of the Agency for Toxic Substances and Disease Registry (ATSDR) to prepare a toxicological profile for each substance on the list provided by the Secretary of Defense under subsection (b).

**CONTRIBUTORS****CHEMICAL MANAGER(S)/AUTHORS(S):**

Zemoria A. Rosemond, B.A.  
ATSDR, Division of Toxicology, Atlanta, GA

Fernando Lladós, Ph.D.  
Research Triangle Institute, Research Triangle Park, NC

**THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:**

1. Green Border Review. Green Border review assures consistency with ATSDR policy.
2. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
3. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
4. Data Needs Review. The Research Implementation Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.





**PEER REVIEW**

A peer review panel was assembled for 4,4'-methylenedianiline. The panel consisted of the following members :

- 1 . Dr. G.A.S. Ansari, Professor, Department of Human Biological Chemistry and Genetics and Pathology, University of Texas Medical Branch, Galveston, TX 77555;
- 2 . Dr. W. Decker, Private Consultant, El Paso, TX 79904; and
- 3 . Dr. E. Sowinski, Vice President, Environmental Health Management and Science, Hudson, OH 44236.

These experts collectively have knowledge of 4,4'-methylenedianiline's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(i)( 13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.



## CONTENTS

FOREWORD .....	v
CONTRIBUTORS .....	vii
PEER REVIEW .....	ix
LIST OF FIGURES .....	xv
LIST OF TABLES .....	xvii
<b>1. PUBLIC HEALTH STATEMENT .....</b>	<b>1</b>
1.1 WHAT IS METHYLENEDIANILINE? .....	1
1.2 WHAT HAPPENS TO METHYLENEDIANILINE WHEN IT ENTERS THE ENVIRONMENT? .....	2
1.3 HOW MIGHT I BE EXPOSED TO METHYLENEDIANILINE? .....	3
1.4 HOW CAN METHYLENEDIANILINE ENTER AND LEAVE MY BODY? .....	4
1.5 HOW CAN METHYLENEDIANILINE AFFECT MY HEALTH? .....	4
1.6 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO METHYLENEDIANILINE? .....	6
1.7 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH? .....	6
1.8 WHERE CAN I GET MORE INFORMATION? .....	7
<b>2. HEALTH EFFECTS .....</b>	<b>9</b>
2.1 INTRODUCTION .....	9
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE .....	9
2.2.1 Inhalation Exposure .....	11
2.2.1.1 Death .....	11
2.2.1.2 Systemic Effects .....	11
2.2.1.3 Immunological and Lymphoreticular Effects .....	15
2.2.1.4 Neurological Effects .....	15
2.2.1.5 Reproductive Effects .....	15
2.2.1.6 Developmental Effects .....	15
2.2.1.7 Genotoxic Effects .....	15
2.2.1.8 Cancer .....	16
2.2.2 Oral Exposure .....	16
2.2.2.1 Death .....	16
2.2.2.2 Systemic Effects .....	17
2.2.2.3 Immunological and Lymphoreticular Effects .....	38
2.2.2.4 Neurological Effects .....	39
2.2.2.5 Reproductive Effects .....	39
2.2.2.6 Developmental Effects .....	40
2.2.2.7 Genotoxic Effects .....	40
2.2.2.8 Cancer .....	41

2.2.3	Dermal Exposure	43
2.2.3.1	Death	43
2.2.3.2	Systemic Effects	44
2.2.3.3	Immunological and Lymphoreticular Effects	50
2.2.3.4	Neurological Effects	50
2.2.3.5	Reproductive Effects	51
2.2.3.6	Developmental Effects	51
2.2.3.7	Genotoxic Effects	51
2.2.3.8	Cancer	51
2.3	TOXICOKINETICS	53
2.3.1	Absorption	54
2.3.1.1	Inhalation Exposure	54
2.3.1.2	Oral Exposure	54
2.3.1.3	Dermal Exposure	55
2.3.2	Distribution	57
2.3.2.1	Inhalation Exposure	57
2.3.2.2	Oral Exposure	57
2.3.2.3	Dermal Exposure	58
2.3.2.4	Other Routes of Exposure	59
2.3.3	Metabolism	59
2.3.4	Elimination and Excretion	60
2.3.4.1	Inhalation Exposure	60
2.3.4.2	Oral Exposure	60
2.3.4.3	Dermal Exposure	62
2.3.4.4	Other Routes of Exposure	63
2.3.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	64
2.4	MECHANISMS OF ACTION	65
2.4.1	Pharmacokinetic Mechanisms	67
2.4.2	Mechanisms of Toxicity	68
2.4.3	Animal-to-Human Extrapolations	69
2.5	RELEVANCE TO PUBLIC HEALTH	69
2.6	BIOMARKERS OF EXPOSURE AND EFFECT	82
2.6.1	Biomarkers Used to Identify or Quantify Exposure to 4,4'-Methylenedianiline	83
2.6.2	Biomarkers Used to Characterize Effects Caused by 4,4'-Methylenedianiline	85
2.7	INTERACTIONS WITH OTHER CHEMICALS	85
2.8	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	86
2.9	METHODS FOR REDUCING TOXIC EFFECTS	86
2.9.1	Reducing Peak Absorption Following Exposure	87
2.9.2	Reducing Body Burden	87
2.9.3	Interfering with the Mechanism of Action for Toxic Effects	87
2.10	ADEQUACY OF THE DATABASE	88
2.10.1	Existing Information on Health Effects of 4,4'-Methylenedianiline	88
2.10.2	Identification of Data Needs	90
2.10.3	Ongoing Studies	98

3. CHEMICAL AND PHYSICAL INFORMATION .....	99
3.1 CHEMICAL IDENTITY .....	99
3.2 PHYSICAL AND CHEMICAL PROPERTIES .....	99
4. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL .....	103
4.1 PRODUCTION .....	103
4.2 IMPORT/EXPORT .....	106
4.3 USE .....	106
4.4 DISPOSAL .....	106
5. POTENTIAL FOR HUMAN EXPOSURE .....	107
5.1 OVERVIEW .....	107
5.2 RELEASES TO THE ENVIRONMENT .....	108
5.2.1 Air .....	108
5.2.2 Water .....	111
5.2.3 Soil .....	111
5.3 ENVIRONMENTAL FATE .....	112
5.3.1 Transport and Partitioning .....	112
5.3.2 Transformation and Degradation .....	114
5.3.2.1 Air .....	114
5.3.2.2 Water .....	114
5.3.2.3 Sediment and Soil .....	115
5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT .....	116
5.4.1 Air .....	116
5.4.2 Water .....	116
5.4.3 Sediment and Soil .....	116
5.4.4 Other Environmental Media .....	116
5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE .....	116
5.6 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES .....	120
5.7 ADEQUACY OF THE DATABASE .....	120
5.7.1 Identification of Data Needs .....	121
5.7.2 Ongoing Studies .....	124
6. ANALYTICAL METHODS .....	125
6.1 BIOLOGICAL SAMPLES .....	125
6.2 ENVIRONMENTAL SAMPLES .....	128
6.3 ADEQUACY OF THE DATABASE .....	131
6.3.1 Identification of Data Needs .....	132
6.3.2 Ongoing Studies .....	133
7. REGULATIONS AND ADVISORIES .....	135
8. REFERENCES .....	141
9. GLOSSARY .....	155

APPENDICES

A.	MINIMAL RISK LEVEL WORKSHEETS .....	A-1
B.	USER'S GUIDE .....	B-1
C.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS .....	C-1

## LIST OF FIGURES

2-1	Levels of Significant Exposure to 4,4'-Methylenedianiline - Inhalation .....	14
2-2	Levels of Significant Exposure to 4,4'-Methylenedianiline - Oral .....	27
2-3	Proposed Metabolic Pathway for 4,4'-Methylenedianiline .....	61
2-4	Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance .....	66
2-5	Existing Information on Health Effects of 4,4'-Methylenedianiline .....	89





**LIST OF TABLES**

2-1	Levels of Significant Exposure to 4,4'-Methylenedianiline - Inhalation .....	13
2-2	Levels of Significant Exposure to 4,4'-Methylenedianiline - Oral .....	18
2-3	Levels of Significant Exposure to 4,4'-Methylenedianiline - Dermal .....	45
2-4	Genotoxicity of 4,4'-Methylenedianiline <i>In Vivo</i> .....	79
2-5	Genotoxicity of 4,4'-Methylenedianiline <i>In Vitro</i> .....	80
3-1	Chemical Identity of 4,4'-Methylenedianiline .....	100
3-2	Physical and Chemical Properties of 4,4'-Methylenedianiline .....	101
4-1	Facilities that Manufacture or Process 4,4'-Methylenedianiline .....	104
5-1	Releases to the Environment from Facilities that Manufacture 4,4'-Methylenedianiline .....	109
5-2	Concentrations of 4,4'-Methylenedianiline in Air/Dermal Pad in Some Working Areas .....	119
6-1	Analytical Methods for Determining 4,4'-Methylenedianiline in Biological Samples .....	126
6-2	Analytical Methods for Determining Biomarkers of 4,4'-Methylenedianiline in Biological Materials .....	129
6-3	Analytical Methods for Determining 4,4'-Methylenedianiline in Environmental Samples .....	130
7-1	Regulations and Guidelines Applicable to 4,4'-Methylenedianiline .....	137

